
15





What is claimed is:

- 1. A method for inhibiting the growth of endothelial cells, comprising delivering to the cells a growth inhibitory amount of a tannic acid, or a pharmaceutically acceptable derivative, metabolite, salt or pro-drug thereof.
- 5 2. A method of inhibiting neovascularization in a tissue, comprising delivering to the tissue an anti-neovascularization amount of a tannic acid, or a pharmaceutically acceptable derivative, metabolite, salt or pro-drug thereof.
 - 3. The method of claims 1 or 2, wherein the delivering is in vitro or in vivo.
- 4. The method of claims 1 or 2, further comprising delivering an effective amount of an agent or therapy selected from the group consisting of anti-angiogenic, anti-tumor, and immune enhancing.
 - 5. A method of treating a disorder associated with pathological neovascularization in a host, comprising administering to a subject a therapeutically effective amount of growth inhibitory amount of tannic acid, or a pharmaceutically acceptable derivative, metabolite, salt or pro-drug thereof.
 - 6. The method of claim 5, further comprising administering to the subject an effective amount of an agent or therapy selected from the group consisting of antiangiogenic, anti-tumor and immune enhancing.
- 7. The method of claim 6, wherein the disorder is selected from the group consisting of arthritic conditions, neovascularization-based dermatological conditions, diabetic retinopathy, Kaposi's Sarcoma, age-related macular degeneration, restenosis, telangectasia, glaucoma, keloids, corneal graft rejection, wound granularization, angiofibroma, Osler-Webber Syndrome, myocardial angiogenesis, psoriatic arthritis and scleroderma.
- 8. The method of claim 7, wherein the disorder is an arthritic condition selected from the group consisting of rheumatoid arthritis, psoriatic arthritis and osteoarthritis.

15

25





- 9. A method for improving the general health and well being of a subject comprising administering to the subject an effective amount of a tannic acid, or a pharmaceutically acceptable derivative, metabolite, salt or pro-drug thereof.
- 10. The method of claim 9, wherein the amount is delivered as a health food 5 supplement.
 - 11. The method of claim 10, wherein the host or subject is an animal.
 - 12. The method of claim 11, wherein the animal is selected from the group consisting of a pet, a farm animal, or a human patient.
- 13. A method for screening for a therapeutic agent for inhibiting neovascularization or endothelial cell growth comprising the steps of:
 - a. contacting the agent with a suitable cell or tissue sample;
 - b. contacting a separate sample of the suitable cell or tissue sample with a therapeutically effective amount of a tannin or a pharmaceutically acceptable derivative, metabolite, salt or pro-drug thereof; and
 - c. comparing the growth of the sample of step (a) with the growth of the sample of step (b), and wherein any agent of step (a) that inhibits the growth to the same or similar extent as the sample of step (b) is a therapeutic agent for inhibiting neovascularization or the growth of endothelial cells.
 - 14. The method of claim 13, wherein the contacting is in vitro or in vivo.
- 20 15. The method of claim 13, further comprising contacting the samples of steps (a) and (b) with an effective amount of an agent or therapy selected from the group consisting of anti-angiogenic, anti-tumor or immune enhancing.
 - 16. A kit for treating a disorder associated with pathological vascularization in a subject, comprising a therapeutically effective amount of a tannic acid, or a pharmaceutically acceptable derivative, metabolite, salt or pro-drug thereof and instructions for use.
 - 17. The kit of claim 16, wherein the disorder is selected from the group consisting of arthritic conditions, neovascularization-based dermatological conditions,



diabetic retinopathy, Kaposi's Sarcoma, age-related macular degeneration, restenosis, telangectasia, glaucoma, keloids, corneal graft rejection, wound granularization, angiofibroma, Osler-Webber Syndrome, myocardial angiogenesis, and scleroderma.

18. The kit of claim 16, wherein the disorder is an arthritic condition selected from the group consisting of rheumatoid arthritis, psoriatic arthritis and osteoarthritis.